Abstract: The present disclosure provides a foam nasal dressing for topically administering an active agent to a nasal cavity and for absorbing fluid discharge. The foam nasal dressing comprises a foamed core portion and a foamed shell portion arranged such that the foamed core portion is at least partially disposed within the foamed shell portion. The foamed shell portion has a porosity of greater than 80% and comprises a first phase-separated polymer and an active agent. The foamed core portion comprises a second phase-separated polymer with the first and second phase-separated polymers being the same or different. The present disclosure also provides a method of forming the foam nasal dressing.

Abstract: A surgical blade assembly includes a blade having side surfaces defining a width greater than its thickness. The surgical blade assembly also includes a reinforcing member having a body portion, and first and second arms extending from the body portion to define a receiving portion. The receiving portion is configured to receive the blade and the first and second arms are configured to abut the side surfaces of the blade. The first and second arms act as a strut to reinforce the blade against external forces applied to the blade. The blade and the reinforcing member may include coupling features to prevent separation of the reinforcing member from the blade. The blade and the reinforcing member may be substantially perpendicular to each other when coupled.

Abstract: The present disclosure provides a foam nasal dressing for topically administering an active agent to a nasal cavity and for absorbing fluid discharge. The foam nasal dressing comprises a foamed core portion and a foamed shell portion arranged such that the foamed core portion is at least partially disposed within the foamed shell portion. The foamed shell portion has a porosity of greater than 80% and comprises a first phase-separated polymer and FIG. 1A an active agent. The foamed core portion comprises a second phase-separated polymer with the first and second phase-separated polymers being the same or different. The present disclosure also provides a method of forming the foam nasal dressing.

Abstract: A surgical blade assembly includes a blade having side surfaces defining a width greater than its thickness. The surgical blade assembly also includes a reinforcing member having a body portion, and first and second arms extending from the body portion to define a receiving portion. The receiving portion is configured to receive the blade and the first and second arms are configured to abut the side surfaces of the blade. The first and second arms act as a strut to reinforce the blade against external forces applied to the blade. The blade and the reinforcing member may include coupling features to prevent separation of the reinforcing member from the blade. The blade and the reinforcing member may be substantially perpendicular to each other when coupled.

Abstract: The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof.

Abstract: The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof.

Abstract: The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof.

Abstract: The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof.

Abstract: The present invention relates generally to the field of pain management. More particularly, the present invention relates to analgesic combinations of an opioid and flupirtine or retigabine which reduce the risk of substance abuse in pain management. Such combinations are referred to as abuse-deterrent fixed dose combinations (FDC).

Abstract: A method for inducing an analgesic response to inflammatory or neuropathic pain by administration of 1-(2-(4-chlorophenyl)-2-hydroxy)ethyl-4-(3,5-bis(1,1 dimethyl)-4-hydroxyphenyl)methyl piperazine, also called CNSB002 or AM-36, either alone or with an opioid and/or a neurokinin (NK) antagonist.

Abstract: The present invention relates to the management of pain (nociceptive, neuropathic, inflammatory and disease related pains), using omega-conotoxins alone or in combination with neuronal excitation inhibitors (analgesics). The invention in particular provides methods, protocols, compositions and devices which treat, alleviate, prevent, diminish or otherwise ameliorate the sensation of pain.

Abstract: The present invention relates generally to the field of pain management, and in particular, the management of neuropathic pain. The present invention further provides methods and compositions that treat, alleviate, prevent, diminish or otherwise ameliorate the symptoms of neuropathic pain without inducing overt sedation. The present invention also contemplates combination therapy using one or more NK antagonists in combination with one or more compounds which decrease or inhibit neuronal excitation in the treatment of pain in association with the treatment of a particular disease condition or pathology.

Abstract: A semiconductor-based optoelectronic device such as a solar cell has an n-type layer and a p-type layer, together forming a p-n junction. Contact regions are formed on the device, with light-receiving regions between contact regions. A window layer is formed over the n-type layer or the p-type layer at the light-receiving region, the window layer promoting reduced carrier recombination at the surface of the n-type or p-type layer, and/or reflection of minority carriers in the n-type or p-type layer towards the p-n junction. The device has a window protection layer formed over the window layer, the window protection layer providing protection from degradation of the window layer during manufacture and/or operation of the device. For GaAs-based devices the window layer may be Al0.9Ga0.1As and the window protection layer may be GaAs. Additionally, an AlAs etch stop layer may be provided over the window protection layer.

Abstract: The present invention relates to the field of pain management, and in particular, the management of inflammatory pain without inducing overt sedation. The present invention features compositions and treatments for inflammatory pain comprising the administration of an amount of an neurokinin (NK) antagonist in combination with a neuronal excitation inhibitor.

Abstract: Opioid tolerance is reduced by treating the patient with a neurosteroid of formula (I) wherein R1 is H or methyl; R2 is OH and R3 is H, or R2 and R3 taken together are O; R4 is H or methyl; R5 and R6 are each H, or R5 and R5 taken together are O; R7 is H or methyl; and R8 is H, OH, —OC(?O)CH3, SH, —SC(?O)CH3, Cl, Br or F.

Abstract: The present invention relates to the use of pregnanes in inducing analgesia, preferably without overt sedation, in a mammal in response to neuropathic pain, and compositions and kits therefore.

Abstract: An infrared photodetector containing a region of semiconductor quantum dots (1), n type doped in the barrier region (2), and sandwiched between respective layers of semiconductors of n type (3) and p type (4). When infrared photons (5) are absorbed, they create electronic transitions (6) from the confined states in the dots (7) to the conduction band (8). This causes the appearance of a voltage between device p (9) and n (10) contacts or the production of an electrical current. In either way, the detection of the infrared light is possible. A low band-pass filter (12) prevents high energy photons (13) from entering the device and causing electronic transitions (14) from the valence (15) band to the conduction band (8).

Abstract: A composition when used as an analgesic comprising a metabolite of a compound of Formula II wherein R1 is H or Me, R2 is OH, R3 is H; or R2 and R3, taken together, are O; R4 is H or Me, R5 and R6, taken together, are O; R7 is H or Me, R8=H, OH, OAc, SH, SAc, Cl, Br, F together with a pharmaceutically acceptable diluent.

Abstract: The invention provides a solid composite material comprising a matrix formed from a particulate or fibrous material and a cured thermosetting resin, wherein the cured thermosetting resin is derived from an oxidative cleavage product selected from aldehydes and peroxides and mixtures thereof formed by the oxidative cleavage of an unsaturated bond in an unsaturated plant or animal oil, other than the ozonolysis cleavage product of cashew nut shell liquid. Also provided is a process for the production of aldehydes and/or peroxides, which process comprises the treatment of a vegetable oil with ozone (e.g. in the presence of an alcohol as a solvent for the oil) so that hydroperoxides are produced, and the reductive cleavages of the hydroperoxides with a reducing sugar.

Abstract: The invention provides the use of a hemicellulose for the manufacture of a composition for use as a vaccine adjuvant. The hemicellulose is preferably an arabinoxylan and more preferably is a crosslinked arabinoxylan such as arabinoxylan ferrulate. Also provided by the invention are vaccine compositions containing a vaccine antigen, or a DNA vaccine, and the hemicellulose, preferably in crosslinked microparticulate form.